ARQT - Arcutis Biotherapeutics Inc

24.59
-0.230   -0.935%

Share volume: 973,183
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$24.82
-0.23
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
48%
Profitability 43%
Dept financing 32%
Liquidity 75%
Performance 51%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.46%
1 Month
-7.52%
3 Months
-16.56%
6 Months
39.01%
1 Year
58.75%
2 Year
144.92%
Key data
Stock price
$24.59
P/E Ratio 
0.00
DAY RANGE
$24.39 - $25.53
EPS 
-$0.09
52 WEEK RANGE
$11.86 - $31.77
52 WEEK CHANGE
$62.20
MARKET CAP 
3.557 B
YIELD 
N/A
SHARES OUTSTANDING 
124.033 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.52
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,388,501
AVERAGE 30 VOLUME 
$1,378,706
Company detail
CEO: Todd F. Watanabe
Region: US
Website: arcutis.com
Employees: 150
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of arq-154.

Recent news